These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Radiosensitizing effects of nitroimidazole derivative, KIN-804].
    Author: Tada T.
    Journal: Nihon Igaku Hoshasen Gakkai Zasshi; 1995 Jan; 55(1):70-5. PubMed ID: 7899069.
    Abstract:
    KIN-804(2-nitroimidazole-1-methylacetohydroxamate) is a new hypoxic cell radiosensitizer developed in Japan. It showed a high level of radiosensitizing effect in vitro experiments and is expected to have low neurotoxicity because of its hydrophilic side chain. In this paper, the in vivo characteristics of KIN-804 were studied. Acute toxicity, pharmacokinetics and radiosensitizing effect were studied using C3H/He mice and SCC VII carcinoma. Misonidazole was used as a standard comparison. LD50/7 was used for the evaluation of acute toxicity. The LD50/7 of KIN-804 and Misonidazole were 3200 mg/kg and 2000 mg/kg, respectively. Pharmacokinetics were studied using high performance liquid chromatography. The concentration of KIN-804 in the tumor peaked 20 min after administration and reached 62% of the maximum concentration in blood. The concentrations in brain and sciatic nerve were low. The radiosensitizing effect was evaluated using the growth delay method. The enhancement ratios of KIN-804 were 1.71, 1.50 and 1.22 at doses of 200, 100 and 50 mg/kg, respectively, compared with 1.36 for Misonidazole at a dose of 100 mg/kg. When irradiation was performed with double fractionation, the enhancement ratio of KIN-804 at a dose of 100 mg/kg decreased to 1.25. Based on these results, KIN-804 is considered a promising radiosensitizer.
    [Abstract] [Full Text] [Related] [New Search]